Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 6INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Dermatologic 1

Conditions

Solid Tumors 1Neoplasms 1Melanoma 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × oblimersen × Clear all
NCT00636545 2012-04-06

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Genta Incorporated

Phase 1 Completed
25 enrolled
Other solid neoplasm

Solid Tumors

NCT00409383 2011-11-07

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Genta Incorporated

Phase 1 Unknown
28 enrolled
Dermatologic

Melanoma

NCT00543231 2007-10-12

A Phase I Study of G3139 Subcutaneous in Solid Tumors

Genta Incorporated

Phase 1 Completed
8 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡